Tesofensine
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Strong appetite suppression and clinically meaningful weight-loss signal, with smaller possible increases in energy expenditure and fat oxidation.
Tesofensine lives or dies on CNS and cardiovascular tolerance: BP, resting HR, sleep, anxiety/mood, serotonergic stacking, and dose creep are the gates.
Strong appetite suppression and clinically meaningful weight-loss signal, with smaller possible increases in energy expenditure and fat oxidation.
CNS and cardiovascular tolerability are the limiter: dry mouth, insomnia, nausea, mood changes, higher heart rate, blood pressure sensitivity, and thin long-term safety data beyond the controlled-trial window.
Most useful when appetite is the bottleneck, not when the user wants a low-friction metabolic add-on. It behaves more like a stimulant-adjacent appetite drug than a GLP-1.
Clinical trials and community reports both point to meaningful appetite suppression, but response varies sharply; some users report dramatic appetite control while others get jitters, sleep disruption, or little weight change.
Intro
Tesofensine is an oral monoamine reuptake inhibitor originally investigated for Parkinson's and Alzheimer's disease, then repurposed for obesity after weight loss appeared in clinical work.
It blocks reuptake of dopamine, norepinephrine, and serotonin, which makes food less rewarding and satiety easier to maintain. In a 24-week obesity trial, daily tesofensine produced dose-dependent weight loss, with 0.5 mg often treated as the practical center of the signal. The tradeoff is not injection logistics or endocrine suppression; it is nervous-system and cardiovascular tolerance, with limited controlled human safety data for open-ended use. Users who already run anxious, hypertensive, insomniac, or stimulant-sensitive need to treat it as a higher-friction appetite tool.
Observed Effects
The clearest observed effect is appetite suppression. In overweight and moderately obese men, a short 2-week study using 2.0 mg daily for 7 days followed by 1.0 mg daily reported 1.8 kg more weight loss than placebo, higher satiety scores, lower hunger, and an 18 g increase in 24-hour fat oxidation. Longer obesity trials reported significant 24-week weight loss, with the corpus repeatedly flagging a 203-person obese-patient trial and practical discussion around 0.5 mg. Tesomet studies in hypothalamic obesity combine 0.5 mg tesofensine with 50 mg metoprolol to blunt heart-rate effects; in that setting, common adverse events included sleep disturbance, dry mouth, and headache. Community reports line up on appetite control, but the split is wide: some users describe sharp appetite shutdown at 0.25-0.5 mg, while others report jitters, insomnia, or no useful loss at the same dose.
Field Reports
Community users most often describe appetite dropping before any body-composition change is visible.
Reports cluster around morning 0.25-0.5 mg use, with some users saying 0.5 mg feels like a clean appetite cutoff and others saying the same dose brings jitters or poor sleep. A recurring practical mistake is stacking it with caffeine or other stimulants and then blaming the compound for avoidable anxiety. Another pattern is expecting GLP-1-like quiet satiety; tesofensine can feel more activating because catecholamines are part of the mechanism. Female-specific experience reports were not well represented in the reviewed evidence, so sex-specific community conclusions should stay conservative.
Community Consensus
Tesofensine has a split reputation. The advocate case is simple: it can shut down appetite hard, it is oral, and older obesity data looked stronger than many legacy weight-loss drugs.
The skeptic case is also simple: it is a brain-chemistry appetite drug, so the limiting side effects are sleep, anxiety, heart rate, and mood rather than injection hassle. Community protocol talk often compares it with GLP-1s, but the comparison is imperfect. GLP-1 drugs slow gastric and incretin signaling; tesofensine changes dopamine, norepinephrine, and serotonin availability. That makes it more attractive to users who dislike GLP-1 nausea or injections, and less attractive to users who already react badly to stimulants. The strongest community read is conditionally bullish: useful appetite leverage, but not a casual wellness compound.
Risks & Monitoring
Tesofensine's adverse-effect profile follows its monoamine mechanism. Norepinephrine and dopamine reuptake inhibition can raise alertness, heart rate, blood pressure, anxiety, and insomnia; serotonin effects can add nausea, dry mouth, appetite change, and mood effects. Clinical and corpus sources repeatedly flag 0.5 mg as more tolerable than higher dosing, but even 0.5 mg can increase heart rate. Tesomet pairs tesofensine with metoprolol because cardiovascular tolerance is central enough to be built into the study design. Trial exclusions around cardiovascular disease, abnormal ECG findings, psychiatric illness, eating disorders, and interacting drugs matter because they are exactly where community misuse can be riskiest. Avoid use in uncontrolled hypertension, arrhythmia history, panic-prone users, bipolar/mania risk, active eating disorder physiology, or anyone combining serotonergic or stimulant drugs without clinician oversight. Stop signals include sustained resting tachycardia, new chest pain, severe anxiety, insomnia that does not resolve with dose timing, agitation, or blood pressure that stays elevated.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Avoid With
Do not combine Tesofensine with the following. Sorted highest-severity first.
Why:Combining monoamine reuptake inhibition with MAO inhibition can dangerously raise monoamine tone.
Why:Additive norepinephrine and dopamine signaling can worsen tachycardia, anxiety, and insomnia.
Why:Tesofensine can raise heart rate and sympathetic tone.
Why:Serotonin reuptake inhibition creates interaction risk and mood-state unpredictability.
Why:Overlapping appetite suppression can drive under-fueling, nausea, dehydration, and poor recovery.
Protocols By Goal
For fat loss, tesofensine fits best when the goal is appetite compliance during a calorie deficit.
Morning dosing, daily blood-pressure checks during the first week, and a hard sleep cutoff matter more than complex cycling. For GLP-1 comparison, it is not a gut-hormone replacement; it changes reward, hunger, and arousal through monoamines, so the user profile is different. For hypothalamic-obesity or disease-state use, the evidence is more clinical but also more medical; the Tesomet studies are physician-supervised and include cardiovascular monitoring. For cognitive or stimulant-adjacent use, the available evidence does not support chasing it as a nootropic; appetite and arousal effects are the real signal.
Dosing Details
Clinical obesity discussion usually centers on 0.25-1.0 mg oral daily, with 0.5 mg/day appearing repeatedly as the practical middle.
A cautious community-style start is 0.125-0.25 mg in the morning for several days, then 0.25-0.5 mg if sleep, heart rate, and blood pressure stay controlled. Avoid late-day dosing because insomnia is one of the most common failure modes. Do not escalate just because appetite is not fully absent; the available evidence repeatedly shows that tolerability, not theoretical potency, sets the ceiling. Tesomet protocols use 0.5 mg tesofensine with 50 mg metoprolol under clinical supervision; that should not be casually copied as a self-managed beta-blocker stack.
Stacks & Alternatives
Sometimes discussed as an appetite-stack partner, but overlapping appetite suppression can worsen under-eating, nausea, dehydration, and poor training output.
Mechanistically redundant for arousal; combining can amplify heart rate, anxiety, and insomnia.
Used in Tesomet clinical protocols to manage heart-rate effects, but beta-blocker pairing belongs in clinician-supervised contexts.
Low-risk support for preserving lean mass and reducing appetite-drug fatigue during a deficit.
Alternatives
Stack Cost
Tesofensine spends stack capacity on CNS arousal and cardiovascular monitoring, not on endocrine suppression or injection logistics.
Monoamine reuptake inhibition can improve appetite control while worsening insomnia, anxiety, agitation, or mood instability.
Heart-rate and blood-pressure sensitivity are central enough that Tesomet trials paired tesofensine with metoprolol.
MAOIs, serotonergic psychiatric drugs, stimulants, and heavy caffeine can overlap with tesofensine's serotonin, norepinephrine, and dopamine mechanism.
It is not a normal approved obesity prescription in the United States, so sourcing and dose accuracy are fragile.
- ·Do not combine with MAOIs.
- ·Keep stimulant and caffeine exposure low until sleep and blood pressure are stable.
- ·Do not stack with aggressive appetite suppressors if protein, hydration, or training output collapses.
- ·baseline and ongoing blood pressure checks
- ·resting heart-rate tracking
- ·sleep and anxiety log
- ·capsule/tablet dose verification when sourced outside regulated channels
Ordinary misuse can create meaningful insomnia, anxiety, tachycardia, blood-pressure problems, and interaction risk.
- ·uncontrolled hypertension
- ·panic disorder or mania history
- ·current MAOI or complex serotonergic medication stack
- ·heavy stimulant or caffeine dependence
There is no HPG suppression or taper requirement in the reviewed evidence; stopping mainly removes appetite control and arousal effects.
- ·appetite rebound
- ·loss of deficit adherence
- ·sleep normalization after overstimulation
Dose only in the morning, reduce caffeine, lower dose, or stop if symptoms persist.
Stop and seek medical review; do not self-add beta blockers to force continuation.
Set protein, fluid, and electrolyte floors before escalating dose.
Sympathetic spillover can make cardiovascular risk the limiting factor.
Dopamine and norepinephrine effects can destabilize mood and sleep.
Mechanism overlap raises interaction risk.
Weight-loss pharmacology and fetal exposure uncertainty make use inappropriate.
Practical Setup
Tesofensine is usually discussed as an oral tablet or capsule. Morning dosing is the practical default because half-life and carryover can make late dosing hostile to sleep.
Product quality is a real issue in gray-market access: small absolute doses mean capsule accuracy and batch identity matter. Users should log morning blood pressure, resting heart rate, sleep latency, appetite, and training output for the first 1-2 weeks before judging dose changes. If appetite suppression makes protein, fluids, or electrolytes fall, the weight-loss signal can come with worse recovery. Cost and availability vary widely because it is not an FDA-approved obesity drug in the United States.
Mechanism Deep Dive
Triple monoamine reuptake inhibition. Tesofensine inhibits reuptake of norepinephrine, dopamine, and serotonin. Functionally, that raises satiety, reward-control, and arousal signaling in ways that can make food less compelling.
Appetite and reward. The strongest practical mechanism is reduced hunger and reduced food reward. Rodent work links appetite suppression to indirect alpha-1 adrenergic and dopamine D1 receptor pathway activity, while human studies show lower hunger and higher satiety after dosing.
Energy expenditure and fat oxidation. Human chamber work found a small nighttime energy-expenditure signal and higher 24-hour fat oxidation, but the main effect is still appetite. Treat thermogenesis as a secondary contributor, not the reason to use it.
Cardiovascular and CNS spillover. The same norepinephrine and dopamine activity that helps appetite can raise heart rate, worsen anxiety, and disrupt sleep. Tesomet's metoprolol pairing is a mechanistic clue: sympathetic effects are not incidental.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
In a 24-week obesity trial, daily tesofensine produced dose-dependent weight loss, with 0.5 mg often treated as the practical center of the signal.
Applies best to obesity-treatment contexts, not lean users seeking minor appetite control.
A 2-week study using 2.0 mg daily for 7 days followed by 1.0 mg daily reported 1.8 kg more weight loss than placebo.
Short-duration high-dose pharmacology study; tolerability may differ from lower community doses.
The same short study reported an 18 g increase in 24-hour fat oxidation.
Fat oxidation was measured in a chamber setting and should not be treated as the main clinical effect.
Tesomet studies in hypothalamic obesity combine 0.5 mg tesofensine with 50 mg metoprolol.
Disease-state, clinician-supervised combination; not a template for self-managed beta-blocker stacking.
Clinical obesity discussion usually centers on 0.25-1.0 mg oral daily, with 0.5 mg/day appearing repeatedly as the practical middle.
Community dosing should be bounded by vitals and sleep tolerance.
Users should log morning blood pressure, resting heart rate, sleep latency, appetite, and training output for the first 1-2 weeks before judging dose changes.
Monitoring interval is a practical safety rule, not a clinical endpoint.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.